https://www.selleckchem.com/pr....oducts/crenolanib-cp
Spline curve analysis was used to define the association between reduced GLVMWE and all-cause death. After a median follow-up of 80 months (interquartile range, 67-97 months), 40 (8%) patients died. Patients with reduced GLVMWE (86%) showed higher cumulative rates of all-cause mortality (17.5% versus 4.7%; log-rank 0.001) in comparison with patients with preserved GLVMWE (≥86%). Reduced GLVMWE (86%) showed an independent association with all-cause mortality (hazard ratio, 3.167 [95% CI, 1.679-5.972]; 0.001).